Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Jan 2 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dr. John M. de Castro who wrote (150)	6/19/1997 12:21:00 AM
From: Miljenko Zuanic	of 1494

John, I didn't read complete article, and even if I did probably I will have little to directly comment on your respond. Today it is well documented that elevated concentration of the EAC -calcium channel receptor agonist are toxic to nerve cells. Also, each EA has activity toward several sub-type receptors. Consequently to this some molecules show activity toward different type receptors. For instance Memantine is agonist for dopamine, and antagonist for glutamate and homocysteine receptors. This relative non-selectivity (IMO any CNS disorder/degeneration drug should have potent selectivity) is positively substituted with very low toxicity. The question is will Memantine have enough positive therapeutic effects for several indication where will compete with other drugs? Still, I do not consider Memantine as direct competitor to Cerestat (maybe it will be in future) for acute stroke. Because the overall health-care system is changing altitude toward "prevention of the disease", Memantine can be, if proved effective, good therapy for stroke prevention. mz

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next